Fig 3. SATA-8505 Fails to Improve MRSA Skin Infection at High MOI.

Lesion size (a), CFU (b), PFU (c), and transcript data (d-f) for mice injected with 10⁹ plaque-forming units (PFU) of SATA-8505 immediately prior to subcutaneous injections of 10⁷ CFU of USA300 processed in an identical manner as MOI of 1 experiments. Data shown are representative of 2–3 independent experiments using 5 or more mice per group, and displayed as mean + s.e.m. Differences were calculated by ANOVA with Bonferroni correction and depict differences from diluent treated wild type unless otherwise noted. ns = not significant, * = p <0.05, ** = p<0.01, *** = p<0.001.